Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Jul;40(1):76–78. doi: 10.1111/j.1365-2125.1995.tb04538.x

The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler.

P W Barry 1, C O'Callaghan 1
PMCID: PMC1365031  PMID: 8527272

Abstract

A multistage liquid impinger was used to determine the amount of budesonide available from the Nebuhaler spacer device following alteration of spacer static charge, delay in sampling from the spacer, and multiple actuations of the metered dose inhaler into the spacer prior to sampling. The mean amount of budesonide (s.d.) recovered per 200 micrograms actuation in particles smaller than 5 microns increased from 30.5 micrograms (8.8) to 69.3 micrograms (17.9) with a low static spacer. A 20 s delay between actuation and inhalation reduced the amount recovered to 10.9 micrograms (3.2), but no reduction was seen when using a low static spacer after the same delay. Multiple actuations into the spacer before sampling also reduced the recovery to 24.8 micrograms (3.4) after two actuations, and 13.5 micrograms (7.6) after five actuations. When using a Nebuhaler with budesonide metered dose inhalers, more respirable drug will be obtained if the aerosol is inhaled immediately after actuation, and multiple actuations into the spacer device are avoided. Low static spacers may also improve drug delivery. Attention to the details of spacer use may reduce the incidence of therapeutic failure and the cost of inhaled medications.

Full text

PDF
76

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry P. W., Robertson C. F., O'Callaghan C. Optimum use of a spacer device. Arch Dis Child. 1993 Dec;69(6):693–694. doi: 10.1136/adc.69.6.693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clark A. R., Rachelefsky G., Mason P. L., Goldenhersh M. J., Hollingworth A. The use of reservoir devices for the simultaneous delivery of two metered-dose aerosols. J Allergy Clin Immunol. 1990 Jan;85(1 Pt 1):75–79. doi: 10.1016/0091-6749(90)90224-r. [DOI] [PubMed] [Google Scholar]
  3. Everard M. L., Clark A. R., Milner A. D. Drug delivery from holding chambers with attached facemask. Arch Dis Child. 1992 May;67(5):580–585. doi: 10.1136/adc.67.5.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Keeley D. Large volume plastic spacers in asthma. BMJ. 1992 Sep 12;305(6854):598–599. doi: 10.1136/bmj.305.6854.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. O'Callaghan C., Cant M., Robertson C. Delivery of beclomethasone dipropionate from a spacer device: what dose is available for inhalation? Thorax. 1994 Oct;49(10):961–964. doi: 10.1136/thx.49.10.961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. O'Callaghan C., Lynch J., Cant M., Robertson C. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug. Thorax. 1993 Jun;48(6):603–606. doi: 10.1136/thx.48.6.603. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES